practical aspects
DESCRIPTION
PRACTICAL ASPECTS. Topics. Getting the trial started at your hospital. How to send your data. Maintaining your Hospital Site File. Patient Information & Consent. Emergency Unblinding . Frequently Asked Questions. How to randomise a patient. Reporting Adverse - PowerPoint PPT PresentationTRANSCRIPT
PRACTICAL ASPECTS
Topics
How to randomise a patient
Trial Materials
Good Clinical Practice Guidance
Frequently Asked
Questions
Maintaining your Hospital
Site File
Reporting Adverse Events
EmergencyUnblinding
Getting the trial started at your hospital
How to send your data
Patient Information & Consent
Trial TreatmentHow to give the
trial drugs
Contacts &further
information
Introduction• Your TRIAL SITE FILE contains all the
information and instructions you need for conducting the trial – please use it
• If you have any questions about the trial please contact the co-ordinating centre staff
BACK TO TOPICS
Getting the trial started (1)
Before the trial can start at your hospitalwe must have the following documents:
• Ethics Approval (local and/or national)• National regulatory approval (if required)• Approval of your hospital (if required)• A signed copy of the Principal Investigator’s
Statement• A copy of our Hospital Information & CV Form• A copy of the approved Patient Information
Sheet & Consent (if different from the protocol sent to you)
CREATEA TRIALTEAM
Nominate someone to be responsible in your absence
Identify people to be responsible for specific
trial process – they must be interested in
the trial
Every speciality must be represented:• Nurses• Traumatologists• Intensivists• General Surgeons• Neurosurgeons• Orthopaedics• Clerical Staff• Pharmacy• Managers• Administrators
Coordinating Centre is also part of your team:o Good communication is essentialo Ask for help & advice if neededo hare your successes and difficulties
Provide information and training about the
trial to all members
Getting the trial started (2)
BACK TO TOPICS
• CRASH-2: involve patients who have suffered serious injuries and are at risk of life threatening haemorrhage
• Most patients will have some impairment in their level of consciousness caused either by blood loss or coexisting head injury
• Patients may not be able to provide written informed consent
• Trial treatment has to be administered as soon as possible after injury
Consent (1)
• Need to comply with local approved consent process
• Should your Ethics Committee require changes to the Patient Information Sheet, please send a copy of the approved version to us – this will be used to provide you with copies in the patient treatment packs.
Consent (2)
Patient Information & Consent• If written consent is required, please
ensure that all the original signed forms are kept in the study Site File
• If you have told us that consent is legally required, we will request confirmation that consent has been obtained
• When requested, please send a copy of the relevant section of your Randomisation Log (found in your Site File)
BACK TO TOPICS
There are two ways to randomise a patient:
RANDOMISE BY TELEPHONE: • Country and hospital must have access to the freecall service.• Your Site File and Randomisation Posters will have the telephone number you need to use – this number is unique to each country• All the information on the Entry Form will be required by the operator• The operator will give you the allocated treatment pack number
Complete the entry form first to ensure the patient fulfils the eligibility criteria. If the patient is suitable for
the trial:
NON-TELEPHONE: •After completing the Entry Form, select lowest numbered treatment pack. •You must send the completed Entry Form to the co-ordinating centre as soon as possible after randomisation
How to randomise a patient (1)
How to randomise a patient (2)
All patients randomised or considered for randomisation must be recorded in your Site
File
BACK TO TOPICS
Trial treatmentEach treatment BOX has:• a 4 digit unique number e.g. 4121• 8 individual patients packs each
numbered with the box/pack number e.g. 4121/21
• Paper Entry Forms• Paper Outcome Forms• Patient Information Sheet/consent
Each treatment PACK has:• 4 ampoules of tranexamic acid/placebo• 100mL bag Sodium Chloride 0.9%• 10 mL syringe• needle
BACK TO TOPICS
How to give the trial drug (1)
ALL AMPOULES ARE IDENTICAL AND CONTAIN 500mg OF
EITHER TRANEXAMIC ACID OR PLACEBO LOADING DOSE - 2 ampoules over 10 minutesGive immediately after randomisationPRESCRIBE: “CRASH-2 Trial (1 gram of tranexamic acid/placebo) over 10 minutes”
• Using syringe provided in the treatment pack draw up 10 mL (2 ampoules of
tranexamic acid / placebo) and add to 100 ml bag of Sodium Chloride 0.9%
provided - Mix well• Fill in date of randomisation on all 6 peelable labels on the cover of the pack
• Peel off a pre-printed INFUSION label and attach to bag • If required, complete and attach a hospital infusion label to bag• Connect infusion to patient’s IV line and infuse over 10 minutes• Peel off a pre-printed DRUG CHART label, place at the front of prescription chart
• Peel off pre-printed randomisation labels and place one on PATIENT MEDICAL
RECORDS, one on ENTRY FORM and one on OUTCOME FORM
TXA solution for injection should not be mixed with blood for transfusion or infusion solutions containing penicillin
ENSURE PATIENT DETAILS ARE RECORDED ON RANDOMISATION LOG IN THE SITE FILE
MAINTENANCE DOSE - 2 ampoules over 8 hours
Start immediately after completion of loading dose
PRESCRIBE: “CRASH-2 Trial (1 gram of tranexamic acid / placebo). Infuse at 60 L/hour”
• Draw up 10mL (2 ampoules of tranexamic acid / placebo) and add to 500mL bag of Sodium Chloride 0.9% (to be provided by trial site)*
• Peel off a pre-printed INFUSION label and attach to bag • If required, complete and attach a hospital infusion label to bag• Connect infusion to patient’s IV line and infuse at 60mL/hour• If infusion is terminated early for any reason, please record end time on
prescription chart
How to give the trial drug (2)
* Or other compatible solutions e.g dextrose 5% and Ringer’s solution
INCOMPATIBILITIES
TXA solution for injection should not be mixed
with blood for transfusion or infusion solutions
containing penicillin.
How to give the trial drug (3)
BACK TO TOPICS
Data Collection (1)
In your Site File you have 3 guidance sheets:
1.How to complete patient entry form2.How to complete the outcome form3.How to send your Entry and Outcome
Data Forms
Please use these to help you send your data
BACK TO TOPICS
Internet: Primary data collection is to be done via the ‘collaborators’ intranet’ on our website www.crash2.lshtm.ac.uk
A username and password to use this site will be sent to you by email before you start the trial. If for any reason you do not receive them, please email [email protected]
Email: data can also be submitted using the ‘electronic data forms’. These forms can be found on a disk at the front of your study site file. We can also email you these forms to you if required.
These two are the preferred methods for sending your data as they will eliminate data queries.
Data Collection (2)
BACK TO TOPICS
If you are using fax to send forms it would be useful to attach a treatment pack sticker on an outcome form ready for use as soon as possible after randomisation. If a treatment pack sticker is no longer available, please write the BOX/PACK number in the box on the top right corner of the form.
Fax to +44 20 7299 4663
POST SHOULD BE USED ONLY AS A LAST RESORT: As there is a delay in us receiving your data, this will disrupt your drug supply. Please photocopy your data forms, keep the original in your Site File and post the copy to: CRASH TRIALS CO-ORDINATING CENTRELondon School of Hygiene & Tropical MedicineKeppel Street, London WC1E 7HTUnited Kingdom
Data Collection (3)
BACK TO TOPICS
Emergency UnblindingIn general there should be no need to un-blind the allocated treatment.
If some contraindication to tranexamic acid develops after randomisation, the trial treatment should simply be stopped.
Unblinding should be done only in those rare cases when the doctor believes that clinical management depends importantly upon knowledge of whether the patient received tranexamic acid or placebo (e.g. suspected anaphylaxis).
In those few cases when urgent unblinding is considered necessary, the randomisation service should be telephoned. The telephone number is in your Site File. Please give your hospital name or ID code and the box/pack number.
BACK TO TOPICS
Record in medical notesSERIOUS NOT SERIOUS
1. Results in death2. Is life-threatening3. Requires hospitalisation or 4. Prolongation of existing hospitalisation 5. Results in persistent or significant disability or incapacity 6. Is a congenital anomaly or birth defect
EXPECTED SIDE EFFECTS LISTED IN PROTOCOL (page 8) DO NOT REQUIRE REPORTING (these are outcome data):
• Death – unless believed to be directly due to the trial treatment• Pulmonary Embolism• Deep Vein thrombosis• Stroke• Myocardial Infarction• Gastro Intestinal Bleeding• Multi-organ failure• Result of trauma suffered by patient• Medical events expected in severe injury
UNEXPECTED SIDE EFFECTS:
1. Complete a Serious Adverse Event Form
2. Telephone Randomisation Service (phone number as per Randomisation Poster or site file) to register Serious Adverse Reaction; give the information on the form
3. Fax/email completed form to the Co-ordinating Centre within 24 hours
Adverse Event Reporting
BACK TO TOPICS
Trial materials
BACK TO TOPICS
BEFORE YOU START THE TRIAL YOU WILL RECEIVE• a site file compiled specifically for your hospital, containing contact details, further information, guidance, spare forms and space for completed data
• training CD with a PowerPoint presentation
• randomisation posters with step by step instructions
TREATMENT PACKS• initially one box of 8 patient packs
• stock level is monitored by received patient entries
• we will send new packs when you reach your minimum stock level which is dependent on your randomisation rate
PROTOCOLS• protocol summaries and pocket cards
TRAINING AND PRESENTATIONSPlease contact the Co-ordinating Centre if • you need more training materials for staff sessions• you are presenting the trial in meetings or conferences
You will soon be able to order all trial materials via the COLLABORATORS’ INTRANET on the trial website www.crash2.lshtm.ac.uk
Investigator’s Master File to be maintained(legal obligation)
• Screened patient – not randomised• Randomisation List• Original Signed Consent Forms (if
required)• Original Data• All correspondence
Site file
BACK TO TOPICS
Question: Is CRASH-2 a Head Injury Trial?Answer: No – All adult trauma patients with ongoing haemorrhage OR at risk of significant haemorrhage can be randomised. Patients with
concurrent head injury can be included.
Frequently asked questions and answers can be found on the trial website & your site filePlease let us know of questions you get asked frequently and we will add these to the website
Example of question:
FAQs
BACK TO TOPICS
CRASH-2 WILL BE CONDUCTED IN ACCORDANCE WITH THE PRINCIPLES OF ICH-GCP
The Principles of ICH-GCP and the Declaration of Helsinki can be found in your Site File.
Full versions can be found on our website
Please be aware of your own country’s GCP Guidelines
Good Clinical PracticeGood Clinical Practice (GCP): is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of human subjects.
Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected in accordance with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible.
BACK TO TOPICS
ContactsEmail addresses are formed like this: [email protected]
Ian RobertsClinical Co-ordinator
Haleema ShakurTrial Manager
Lin BarnetsonData Manager
Maria RamosAdministrator
Donna ToothAssistant Co-ordinator
Pablo PerelResearch Fellow
(Spanish Speaker)
Phil EdwardsResearch Fellow
Tony BradyProgrammer
BACK TO TOPICS